Cure My Disease

Don't miss your cure!

 Log in / Sign up

Thyroid cancer trial tests faster hormone control after radioiodine

NCT ID NCT06647602

Not yet recruiting Disease control Sponsor: University Medical Center Groningen Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study will enroll 40 people with high-risk differentiated thyroid cancer who need radioactive iodine therapy. After stopping their own thyroid hormones, participants will receive either standard levothyroxine alone or levothyroxine plus liothyronine. The goal is to see which approach brings thyroid-stimulating hormone (TSH) to the target level more quickly, which may help manage the disease better.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
levothyroxine and liothyronine (thyroid hormone replacement drugs)
What this could lead to
If successful, this could show that adding liothyronine to standard levothyroxine helps thyroid cancer patients reach target hormone levels more quickly after radioiodine treatment.
What could go wrong
This is a small, early-stage study (40 participants) that only measures short-term hormone levels, not long-term cancer outcomes. The results may not apply to all thyroid cancer patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFERENTIATED THYROID CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

differentiated thyroid carcinoma thyroid cancer Thyroid Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIFFERENTIATED THYROID CANCER LEVOTHYROXINE LIOTHYRONINE THYROID CANCER THYROID HORMONES

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Radboud University Nijmegen

    Nijmegen, Netherlands

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University Medical Center Groningen (UMCG)

    Groningen, Provincie Groningen, 9700RB, Netherlands

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.